ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 2212 • ACR Convergence 2024

    Seropositive Arthralgias: A Comprehensive Analysis of the Reuma-Check Cohort

    Rodrigo Garcia Salinas1, Felicia Almada2, Gisel Reyes-Jara2, Ronald Perez-Andocillas2 and Sebastian Magri3, 1Hospital Italiano La Plata, La Plata, Argentina, 2Hospital Italiano de La Plata, La Plata, Argentina, 3Hospital Italiano La Plata, Melchor Romero, Argentina

    Background/Purpose: To estimate the frequency of seropositive arthralgia (SA) in a large cohort of patients evaluated for arthralgia in Reuma-check program. To compare the features…
  • Abstract Number: 2230 • ACR Convergence 2024

    Relationship Between the Complement System and Serum Lipid Profile in Patients with Rheumatoid Arthritis

    Maria Garcia-Gonzalez1, Fuensanta Gomez-Bernal2, Juan Carlos Quevedo-Abeledo3, Miguel Angel Gonzalez-Gay4 and ivan Ferraz-Amaro5, 1Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, 2Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 3Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, 4University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 5Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain

    Background/Purpose: The complement system has been linked to the etiopathogenesis of rheumatoid arthritis (RA). Patients with RA exhibit a dysregulated profile of lipid molecules, which…
  • Abstract Number: 2246 • ACR Convergence 2024

    Safety and Efficacy of Cannabidiol in Rheumatoid Arthritis Patients: A Phase 1B Pilot Randomized Placebo Controlled Trial

    Veena Ranganath1, Holly Wilhalme2, Nicolette Morris3, Jenny Brook2, Mihaela Taylor1, Howard Yang1, Tanaz Kermani4, Thanda Aung2, Brian Skaggs1, David Elashoff5 and ziva Cooper6, 1UCLA, Los Angeles, CA, 2UCLA, Los Angeles, 3The University of Queensland Medical School, Ochsner Clinical School, New Orleans, LA, 4University of California Los Angeles, Santa Monica, CA, 5UCLA Department of Medicine Statistics Core, Los Angeles, 6UCLA Center for Cannabis and Cannabinoids, Semel Institute for Neuroscience & Human Behavior, Dept of Psychiatry and Biobehavioral Sciences, Dept of Anesthesiology and Perioperative Medicine, Los Angeles

    Background/Purpose: There is no cure for rheumatoid arthritis (RA) and remission rates vary greatly 10-60%; thus, there is an unmet need for safe adjunctive therapeutic…
  • Abstract Number: 2267 • ACR Convergence 2024

    A Novel Blood-based Assay That Predicts Clinical Response to TNFα Inhibitors or Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis

    Maggie Louie1, Signe Fransen2, Katherine Dilger1, Kevin Lai1, Diana Abdueva3, David Chernoff4 and Jeffrey Curtis5, 1Aqtual Inc, Hayward, CA, 2Aqtual Inc., sf, CA, 3Aqtual Inc., Hayward, CA, 4SetPoint Medical, Sausalito, CA, 5University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Current rheumatoid arthritis (RA) treatments, including TNFa inhibitors (TNFi) and JAK inhibitors (JAKi), have transformed the management of RA by controlling symptoms and slowing…
  • Abstract Number: 2284 • ACR Convergence 2024

    Real-World Evidence of the Antifibrotic Nintedanib in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 74 Patients from Clinical Practice

    Belén Atienza-Mateo1, Ana Serrano-Combarro2, Jesús Loarce3, Nuria Vegas Revenga4, María Martín López5, Santos Castañeda6, Rafael Benito Melero-Gonzalez7, Natalia Mena Vázquez8, Carmen Carrasco-Cubero9, Carolina Díez Morrondo10, David Castro-Corredor11, Tomás Vázquez Rodríguez12, Andrea García-Valle13, Gema Bonilla14, Marina Rodriguez15, Ignacio Brana Abascal16, Sara María Rojas Herrera17, Juan Camilo Sarmiento-Monroy18, Pablo Andújar-Brazal19, Diego Ferrer20 and Ricardo Blanco-Alonso21, and Rest of the Members of the Spanish Collaborative Group of Antifibrotics in Interstitial Lung Disease Associated with Rheumatoid Arthritis, 1Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 3Ramón y Cajal University Hospital, Madrid, Madrid, Spain, 4Hospital Galdakao- Usansolo, Galdakao, Spain, 5General University Hospital of Ciudad Real, Ciudad de México, Spain, 6Hospital Universitario de la Princesa, Madrid, Spain, 7CHU Ourense, O Carballino, Spain, 8IBIMA, Málaga, Andalucia, Spain, 9Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 10Complejo Asistencial Universitario de Leon, Leon, 11General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, 12Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain, 13Hospital General Río Carrión, Palencia, Spain, 14H. Universitario La Paz, Madrid, Spain, 15Hospital Clínico Universitario de Santiago, La Coruna, Spain, 16Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, 17Hospital de Mérida, Badajoz, Spain, 18Hospital Clínic Barcelona, Barcelona, Spain, 19Hospital Universitario Doctor Peset, Valencia, Spain, 20Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 21Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a serious complication of rheumatoid arthritis (RA), with a prevalence that ranges from 7 to 30% patients with RA,…
  • Abstract Number: 2590 • ACR Convergence 2024

    Pesticide Use and Incident Rheumatoid Arthritis Among Spouses in the Agricultural Health Study: An Updated Analysis

    Christine Parks1, Karen Costenbader2, Laura Beane Freeman3, Jonathan Hofmann3 and Dale Sandler4, 1National Institute of Environmental Health Sciences, Epidemiology Branch, Rese, 2Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, 3National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, 4Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC

    Background/Purpose: Systemic autoimmune rheumatic diseases have been associated with farming exposures, but the role of pesticides has not been well studied. The Agricultural Health Study…
  • Abstract Number: 2676 • ACR Convergence 2024

    Timeframe for Initiating Methotrexate and Vaccine Response Against Pneumococcus in Rheumatoid Arthritis: The VACIMRA Study

    Jacques MOREL1, Emmanuelle Dernis2, christian roux3, Christophe Richez4, OLIVIER BROCQ5, Bruno Fautrel6, Carine SALLIOT7, Olivier Vittecoq8, Xavier Mariette9, Frédéric LIOTE10, Slim Lassoued11, Cécile Gaujoux-Viala12, Arnaud Constantin13, MArtin Soubrier14, Valerie Devauchelle15, Vincent Goeb16, Jacques-Eric Gottenberg17, Hubert Marotte18, Annouc Rémy Moulard1, Corinne Merle de Boever1, Héléna Huguet1, Odile Launay19, Florence Galtier1 and Marie Christine Picot1, and F-CRIN networks iREIVAC and CRI-IMMIDIATE, 1CHU and University of Montpellier, Montpellier, France, 2CH LE MANS, LE MANS, Pays de la Loire, France, 3rheumatology department, university Cote d'Azur, nice, France, 4Université de Bordeaux, Bordeaux, France, 5Service de Rhumatologie, centre hospitalier Princesse-Grâce, Monaco, Monaco, 6INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, 7CHU and University of Orléans, Orléans, France, 8CHU and University of Rouen, Rouen, France, 9Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, 10CHU and University of Paris Nord, Paris, France, 11CH of Cahors, Cahors, France, 12CHU Nîmes, Nïmes, Languedoc-Roussillon, France, 13Hôpitaux de Toulouse, Toulouse, France, 14Gabriel-Montpied Hospital, Clermont-ferrand, France, 15UBO, Brest, France, 16CHu and University of Amiens, Ameins, France, 17Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 18Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, 19Centre d’Investigation Clinique en Vaccinologie (CIC Cochin Pasteur), Hôpital Cochin, Paris, Ile-de-France, France

    Background/Purpose: Pneumococcal vaccination is recommended for patients with chronic inflammatory rheumatism treated with immunosuppressants. Methotrexate (MTX) is the first-line treatment used in rheumatoid arthritis (RA),…
  • Abstract Number: 0032 • ACR Convergence 2024

    Increased Expression of Malondialdehyde-Acetaldehyde and Citrullinated Proteins in Myocardial Tissues During the Early Evolution of Collagen-Induced Arthritis

    Wenxian Zhou1, Michael Duryee2, Nozima Aripova2, Jill Poole2, Carlos Hunter2, Amy Nelson2, Tate Johnson2, Daniel Anderson3, Geoffrey Thiele2 and Ted Mikuls2, 1University of Nebraska Medical Center, Bellevue, NE, 2University of Nebraska Medical Center, Omaha, NE, 3University of Nebraska Medical Center, Durham, NC

    Background/Purpose: The risk of heart failure (HF) is increased in patients with rheumatoid arthritis (RA), although mechanisms of myocardial dysfunction underlying HF development in RA…
  • Abstract Number: 0048 • ACR Convergence 2024

    Role of the Chemokine CCL22 in Rheumatoid Arthritis Development

    Marcelo Afonso1, Masa Filipovic1, Alexandra Argyriou2, Alexandra Circiumaru3, Mikael Ringh1, Konstantin Carlberg1, Vijay Joshua1, Szu-Jing Chen1, Marianne Engström1, Heidi Wähämaa1, Tomas Ekström1, Marc H Wadsworth II4, Ravi Kumar1, Aaron Winkler5, Vivianne Malmström1, Anca Catrina1, Karine Chemin1, Aase Hensvold1 and Bence Réthi1, 1Karolinska Institutet, Stockholm, Sweden, 2Karolinska Institutet, Solna, Sweden, 3Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm region, Stockholm, Sweden, 4Pfizer, Cambridge, 5Pfizer Inc., Cambridge, MA

    Background/Purpose: Understanding alterations of the immune homeostasis in individuals at risk of rheumatoid arthritis (RA) can be a key to achieve earlier diagnosis and prevention.…
  • Abstract Number: 0066 • ACR Convergence 2024

    Association Between Gut Microbiota, Inflammation, and Epigenetics in Rheumatoid Arthritis Patients

    jose Manuel Lisbona-Montañez1, Arkaitz Mucientes2, Patricia Ruiz-Limón3, Gracia María Martín-Nuñez4, Rocio Redondo-Rodríguez4, Laura Cano-García4, Sara Manrique-Arija5, Isabel Moreno-Indias2, Natalia Mena Vázquez6 and Antonio Fernández-Nebro7, 1University of Malaga, Malaga, Andalucia, Spain, 2IBIMA Plataforma BIONAND, Malaga, Andalucia, Spain, 3IBIMA, Instituto de Biomedicina de Málaga, Cordoba, Spain, 4IBIMA Plataforma Bionand, Malaga, Spain, 5Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, 6IBIMA, Málaga, Andalucia, Spain, 7Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain

    Background/Purpose: The etiology of rheumatoid arthritis (RA) is not entirely known. Epigenetic modifications could be the link between genetic and environmental factors related to the…
  • Abstract Number: 0172 • ACR Convergence 2024

    Effectiveness of mRNA COVID-19 Vaccines in Patients with Rheumatologic Conditions on Immunosuppressive Therapies

    Brandon Levian1, Charlotte Botz2, Jason Chwa2, Sophie Grove2, Vignesh Ravi2, Branden Ireifej3, daniel arkfeld4, Diana Hanna2, Jenny Hu2 and Binh Ngo2, 1Keck School of Medicine, Beverly Hills, CA, 2Keck School of Medicine, Los Angeles, 3LAGMC/Keck School of Medicine, Los Angeles, CA, 4Keck Medical Center of USC, RANCHO PALOS VERDES, CA

    Background/Purpose: Despite extensive data supporting the effectiveness of mRNA vaccines against SARS-CoV-2 in immunocompetent individuals, their efficacy in immunosuppressed patients remains uncertain. Consequently, this study…
  • Abstract Number: 0294 • ACR Convergence 2024

    Obesity and Risk of Autoimmune Diseases: Insights from the National Inpatient Sample

    Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY

    Background/Purpose: Obesity has been implicated as a risk factor in developing various cardiovascular, respiratory, and other health complications. However, the link between obesity and autoimmune…
  • Abstract Number: 0437 • ACR Convergence 2024

    Describing Maternal Outcomes Among Veterans with a History of Systemic Lupus Erythematosus and Rheumatoid Arthritis

    Deirdre Quinn1, Florentina Sileanu1, Gregory Procario1, Shannon Mitchell1 and Mehret Birru Talabi2, 1VA Pittsburgh Healthcare System, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Veterans who utilize Department of Veterans Affairs (VA) maternity benefits, nearly half (42%) of whom represent racial or ethnic minority groups, have a high…
  • Abstract Number: 0469 • ACR Convergence 2024

    SCORE2 Is Superior to SCORE in Predicting the Presence of Carotid Plaques and Intima-media Thickness in Rheumatoid Arthritis Patients: A Cross-sectional Study with Carotid Ultrasound

    Cristina Campos Fernández1, Jorge Juan Fragío Gil2, Roxana González Mazario3, Pablo Martínez Calabuig4, Laura Salvador Maicas5, Mireia Lucía Sanmartín Martínez6, Iván Jesús Lorente Betanzos6, Clara Molina Almela6, juan José Lerma Garrido7, Amalia Rueda3 and Jose A Román-Ivorra8, 1Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, 2Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, 3Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, 4HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, 5Consorcio Hospital General Universitario de Valencia, Castellón de la Plana, Comunidad Valenciana, Spain, 6Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, 7Hospital General Universitario Valencia, Valencia, Comunidad Valenciana, Spain, 8Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain

    Background/Purpose: Rheumatoid arthritis (RA) escalates the risk of premature mortality, predominantly through cardiovascular diseases. Although SCORE and its updated version, SCORE2, are employed to assess…
  • Abstract Number: 0486 • ACR Convergence 2024

    Associations Between Frailty and Incident Cancer and Cancer-related Mortality in Veterans with Rheumatoid Arthritis

    Bhavik Bansal1, Aaron Baraff2, Katherine Wysham3, James Andrews4, Bryant England5, Ted Mikuls5, Joshua Baker6, Kaleb Michaud5, Alexa Meara7, Una Makris8, Carolyn Presley9, ariela orkaby10 and Namrata Singh11, 1All India Institute of Medical Sciences, New Delhi, Delhi, India, 2VA PUGET SOUND SEATTLE, Seattle, WA, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Nebraska Medical Center, Omaha, NE, 6University of Pennsylvania, Philadelphia, PA, 7The Ohio State University Wexner Medical Center, COLUMBUS, OH, 8UT Southwestern Medical Center and Dallas VA, Dallas, TX, 9The Ohio State Medical Center, Columbus, OH, 10New England VA Geriatric Research Education and Clinical Center/Boston VA/Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 11University of Washington, Bellevue, WA

    Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of cancer compared to the general population. Aging is one of the most important risk…
  • « Previous Page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology